Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):389-93. doi: 10.1007/s00534-009-0231-2. Epub 2009 Nov 19.
We introduce recent advances in surgical techniques and perioperative management in liver resection for hepatocellular carcinoma (HCC).
Our approaches to further enhancing the efficacy of resection for HCC, based on our presentation at "The 6th International Meeting of Hepatocellular Carcinoma: Eastern and Western Experiences" held in Seoul in December 2008, are presented, along with a review of recent advances in this field reported from eastern Asia.
In our series, liver resection enabled a 5-year overall survival rate of close to 60%, even among patients with multiple HCCs and those with portal hypertension in a background of Child-Pugh class A cirrhosis. Favorable long-term results were obtained by the precise evaluation of liver function using the indocyanine green (ICG) test and the application of perioperative treatments for gastroesophageal varices and severe thrombocytopenia. Furthermore, promising novel techniques have been applied to increase the efficacy of HCC resection, including the preoperative simulation of liver resection, using three-dimensional computed tomography, a "peeling-off" technique for resecting HCC with macroscopic portal venous tumor thrombus, ICG-fluorescent imaging, predeposit autologous plasma transfusion, and laparoscopic liver resection.
The safety and accuracy of liver resection for HCC has been continuously enhanced by advances in surgical techniques and perioperative care. Given that the resection of HCC offers a satisfactory overall survival rate for patients with portal hypertension and those with oligonodular multiple tumors, the surgical indications can now be expanded to include such second-best candidates.
我们介绍了肝细胞癌(HCC)肝切除术中手术技术和围手术期管理的最新进展。
我们提出了进一步提高 HCC 切除术疗效的方法,这些方法是基于我们在 2008 年 12 月在首尔举行的“第六届国际肝细胞癌会议:东西方经验”上的演讲,并结合了对东亚地区该领域最新进展的回顾。
在我们的系列中,即使在背景为 Child-Pugh 分级 A 肝硬化的多发 HCC 和门脉高压患者中,肝切除也能使 5 年总生存率接近 60%。通过使用吲哚菁绿(ICG)试验精确评估肝功能和应用门脉高压和严重血小板减少症的围手术期治疗,获得了良好的长期结果。此外,还应用了一些有前途的新技术来提高 HCC 切除术的疗效,包括使用三维 CT 对肝切除术进行术前模拟、对伴有宏观门脉肿瘤血栓的 HCC 进行“剥离”技术、ICG 荧光成像、预存自体血浆输血和腹腔镜肝切除术。
通过手术技术和围手术期护理的进步,HCC 肝切除术的安全性和准确性不断提高。鉴于 HCC 切除术可为门脉高压和寡结节性多肿瘤患者提供满意的总生存率,现在可以扩大手术适应证,包括这些次优候选者。